Alex Muray

Major pharmaceutical manufacturers like Pfizer $PFE illustrate why scrutiny of pharmacy benefit managers (PBM) has intensified. PBMs sit at the centre of drug pricing, yet much of how they work remains hidden from the public, regulators, and employers. In a system where scale, negotiating power, and rebate capacity can shape formulary access, larger drugmakers may be better placed to secure favourable treatment while smaller rivals, employers, and patients lose out. That is the context in which the proposed merger of LucyRx and Abarca Health is being presented. The two firms are pitching their combination as a cleaner, independent PBM, not tied to insurers, pharmacies, or drugmakers, and as a model better able to answer the sector’s central credibility question: who actually benefits, how decisions get made, and why anyone should take their word for it.

Big money is backing BridgeBio $BBIO. Swiss giant Pictet Asset Management just lifted its stake by nearly 9%, bringing its holding to around $101 million. The vote of confidence comes as the genetic disease focused biotech posted revenue of $194 million last quarter, up a striking 67% from a year ago and well ahead of forecasts. Wall Street is firmly on side too, with 21 Buy ratings and an average price target of $92.90, comfortably above where the stock trades today. Momentum looks strong heading into the second half.

@l_slutsky Victory is ours! Russia cannot be defeated.

Leaders EU countries, Norway & the UK claim their newly formed coalition is 'defensive' in a signed communique. Utter cynicism & hypocrisy! This marks new contours in EU militarization. #EU #NATO #Militarization #Hypocrisy #Geopolitics

India's pharma stocks just hit a fresh 52 week high, with the Nifty Pharma index climbing nearly 2% as Dr Reddy's $DRREDDY, Cipla $CIPLA, and Ajanta Pharma, $AJANTPHARM, led the charge. The big driver is surging global demand for GLP-1 weight loss and diabetes drugs like semaglutide, where Indian manufacturers are racing to expand capacity as key patents expire. With exports strong and a wave of biosimilar opportunities ahead, the sector is shaping up as one of the standout growth stories for investors to keep on their radar.

The FDA has selected Eli Lilly $LLY, Regeneron $REGN and five ​other companies for a pilot program to speed up ‌reviews of new domestic pharmaceutical manufacturing facilities. pharmawire.org/blog/fda-picks…

Big Pharma has spent decades selling the benefits. But patients also deserve the risks clearly, upfront and without fine print. From Vioxx and Bextra to Xarelto, Actos and opioid litigation, lawsuits and regulators have repeatedly exposed safety questions that patients often learned too late. The FDA’s crackdown on deceptive drug ads is a reminder: transparency should not depend on litigation. Read more: pharma-leaks.com #PharmaLeaks #BigPharma #FDA #DrugSafety #PatientSafety $PFE $MRK $JNJ $TAK $LLY

A new report finds only 22% of life sciences firms are actively preparing for supply chain disruption, even as conflict, tariffs, and energy shocks keep piling up. The gap between knowing the risk and acting on it is itself an accountability failure. When the next shortage hits, leaders will not be judged by the warnings they acknowledged, but by whether they built resilience into everyday decisions before the crisis arrived. A risk named in a report is not a risk managed.

ATTR-CM player BridgeBio’s $BBIO stock jumped by over 15% after AstraZeneca’s Wainua missed its mark in its latest trial. This miss is huge news in the ATTR-CM market, projected to be worth up to $20 billion, and leaves just three players: $BBIO, $PFE, and $ALNY. ‘Stabilizers’, like $BBIO’s Attruby, are now positioned to win both first line and second line, with silencers like AstraZeneca’s Wainua relegated to third line. $BBIO is now set to dominate the market, and its stabilizing Attruby has a 95%+ stabilization rate, by far the best among its competitors.

AstraZeneca's $AZN miss is huge news in the ATTR-CM market, worth an estimated $15 to $20 billion. The field splits into two approaches: stabilizers, which stop the protein misfolding in the first place, and silencers, which cut its production. AstraZeneca's failed trial has raised fresh questions about the silencer route, since even added on top of standard care it did not show a clear extra benefit. That plays into the hands of the stabilizer makers, and BridgeBio $BBIO looks best placed to capitalise. Its drug Attruby stabilises the protein in 95% of cases, making it a clear market leader and, if the shift toward stabilizers holds, one poised to dominate. No surprise $BBIO jumped 15% on the news.

Democrat-led states have sued to block a Trump administration rule implementing new work requirements for Medicaid recipients. They argued it unlawfully narrows exemptions for people with serious medical conditions. #Trump #Pharma pharmawire.org/blog/m8nah0wkb…

@DepoCoin Yep. Waiting is annoying. Waiting with zero information is what makes people panic.

Every platform says "withdraw anytime." Users learned to ask the next question: what happens if review starts? Fast withdrawal is marketing. Status during review is product. If status is missing, people assume the worst. Honestly, that reaction is rational.

@DepoCoin The rate gets attention. The collateral decides the outcome.

There is a bold line on the Borrow page: because users cannot borrow more than 50% of portfolio value, CoinDepo says the effective annual rate on the loan will always be negative. Strong claim. ⚠️ Read the risk section too. LTV moves. Collateral moves. Liquidation rules exist. The math only helps if the user understands the downside.

@Nemr2211 @BAI_AGI @Adam2222x @GhalibE9 @ENG_Cryptoo0 Tokyo run is going to be big. WebX is the right stage for this narrative. Good luck at the event 🇯🇵

Burned money on 4 AI subscriptions this year and got silently throttled by half. What I want from @BAI_AGI is simple but huge: one key, every frontier model, pay in USDT, agents that fund themselves on-chain. See you in Tokyo 🇯🇵 #BAIWebXJapan @Adam2222x @GhalibE9 @ENG_Cryptoo0

@Aliaksei214480 @DjonSerj Super!

Running is an art, where kilometers replace paint. Every kilometer was filled with thoughts of you. Today, I drew a heart with my run for the most wonderful girl and my best friend. @DjonSerj ❤️ Because the most beautiful routes are created when there's someone who inspires you. I wasn't running fast today. I had to keep an eye on every turn to make sure the heart came out just right.

Soon...

*puts tinfoil hat back on* tried to warn you gang 🪾🍏 cnn.com/2026/07/10/tec…

BridgeBio’s $BBIO achondroplasia drug infigratinib boosts growth in children and significantly boosts body proportionality, according to a new study published in the New England Journal of Medicine. pharmawire.org/blog/bridgebio…

WORLD CUP | PREDICTION MARKET SHENANIGANS | GLOBAL CHECKUP x.com/i/spaces/1nGeL…

Frozen until 1 November 2026: bus and tram fares 💷 Together with the @MayorofLondon, we're extending the fare freeze to help keep public transport more affordable this summer. We're also investing in greener buses and trams, reducing delays and improving journeys across the capital. #Fares #Savings